Skye Bioscience Announces Special Virtual Investor Presentation
Skye Bioscience, Inc. (OTCQB: SKYE) announced a virtual investor presentation scheduled for October 12, 2021, at 1 p.m. ET, focusing on the company's strategic direction for 2022 and updates on its glaucoma treatment program. The event will feature Skye's management team and advisory board members, followed by a Q&A session. Investors can submit questions by September 28, 2021, and must register in advance to attend. Skye is dedicated to developing cannabinoid-derived therapies for significant health issues, with its lead program targeting glaucoma.
- Announcement of a virtual investor presentation may enhance investor engagement.
- Updates on the glaucoma program could attract interest in ongoing clinical developments.
- No immediate financial metrics or significant business progress reported.
SAN DIEGO, CA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will host a special virtual investor presentation on Tuesday, October 12. The filmed broadcast of this virtual event will be available beginning at 1 p.m. ET/10:00 a.m. PT.
The agenda will include the company’s strategic direction and business outlook for 2022, clinical development updates on the company’s lead glaucoma program, R&D advancements and new initiatives, followed by Q&A. Speakers for this event will include Skye’s executive management team in addition to select members of its scientific and clinical advisory boards.
Questions may be submitted for consideration for this special event to ir@skyebioscience.com on or before September 28, 2021. All investors and analysts are requested to register in advance of the event. Registration is available via https://bit.ly/3lnmLO3 or via the Company’s Investor Relations website at https://ir.skyebioscience.com/.
About Skye Bioscience
Skye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company’s lead program, THCVHS, is focused on treating glaucoma, the world’s leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com.
CONTACT
Karam Takhar
VP, Corporate Development & Investor Relations
Email: ir@skyebioscience.com
Phone: (858) 410-0266
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
Attachment
FAQ
What is the date of Skye Bioscience's investor presentation?
What will be discussed during the Skye Bioscience investor presentation?
How can questions be submitted for the Skye Bioscience presentation?
Who will be speaking at the Skye Bioscience investor presentation?
